Anti-smoking drugs in health basket

Health basket to include

December 23, 2009 13:06
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Following days of deliberations and controversy over Deputy Health Minister Ya'acov Litzman's dental care decision, the Committee for Recommending Additions to the Basket of Health Services on Wednesday revealed the 80 new drugs and technologies which will be added to the health basket this year. The drugs, which will aid about 70,000 patients, include anti-smoking medication such as Zyben and Champix, to be handed out free of charge to 6,000 patients undergoing detoxification at a cost of NIS 6.6 million. "The most expensive oncologic drug could not prevent years of disease the way anti-smoking drugs can," said council head Prof. Rafi Bi'or. The council did its best to meet the needs of cancer and kidney patients. In 2010, 140 myeloma patients will be able to acquire Revlimid, a thalidomide shown to be an effective secondary treatment method. 500 psoriasis patients will be given biologic drugs, while women afflicted with advanced stages of breast cancer would be able to receive Tykerb or Herceptin. Those afflicted with Parkinson's disease, meanwhile, would be entitled to Azilect tablets, said to slow the deterioration of the patient's condition. Kidney cancer patients were allotted the most expensive drug in the basket, at a cost of NIS 34 million. Alzheimer's patients and schizophrenics will also receive cutting-edge treatment as a result of the council's decision.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia